News Sentiment

BHVN sentiment intelligence

Biohaven Ltd. news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.

Chart Weekly report Factors RSS feed
Weighted score 52 Balanced news tone 61 relevant articles
Exchange NYSE United States
Sector Healthcare Market context
Industry Biotechnology Read-through group
Latest close 15.55 Week of 10 Jul 2026
Weighted tone 52/100

Balanced news tone

Market reaction Balanced read

News tone and price action are not far from neutral.

Primary event Market update

79/100 classification confidence.

Company focus 53

directly relevant articles

Source quality 1

high-authority source matches

Trend context Trend active

-2.6% over one week, +37.9% over four weeks, trend active, and below fair value.

Latest direct headline Neutral

Price to earnings forward of Biohaven Ltd. – BOATS:BHVN

Market Reaction

Balanced read

60/100 confidence

News tone and price action are not far from neutral.

Primary event Market update 79/100 classification
One-week reaction -2.6% Price reacting lower
Trend fit Trend active 37.9% over four weeks
Fair value -42.9% Below fair value
Value support

Sentiment Mix

Positive, neutral, negative

Weighted by relevance
Positive 14
Neutral 39
Negative 8

Relevance

Why the article matched

Direct first
Direct company coverage 53
Industry context 8
Sector context 0

Sources

Coverage mix

Publishers
Market source 10
Stock Titan 10
PR Newswire 6
TradingView 5
Moomoo 5
Sahm 3
Investing.com 2
simplywall.st 2

Event Lens

What the news is about

Classified themes
Market update 32
Earnings 17
Analyst action 7
Regulatory and legal 3
Deals and strategy 1
Guidance 1

Sentiment Trail

Score over time

50 baseline
Above 50 Neutral zone Below 50

News Tape

Relevant headlines

Showing 31-60 of 61
PR Newswire Direct company coverage

Biohaven Completes Enrollment in RISE 3 Pivotal Focal Epilepsy Study with Opakalim, a Selective Kv7.2/7.3 Activator

Biohaven Ltd. has announced the completion of enrollment in RISE3, a pivotal Phase 2/3 study for its selective Kv7.2/7.3 channel activator, opakalim, for refractory focal epilepsy. Top-line results are anticipated in the second half of 2026. This study aims to provide a new treat

Tone
Positive 74/100
Event
Earnings
Published
30 Jun 2026 07:30
Source
PR Newswire
GuruFocus Direct company coverage

Biohaven (BHVN) Shares Decline Nearly 10% Amid Market Fluctuatio

Biohaven Pharmaceuticals (BHVN) experienced a significant 9.8% stock decline on June 29, 2026, dropping to $14.28, reflecting market volatility and challenges for the clinical-stage biopharmaceutical company. The company has a low GF Score™ of 30/100 and a low profitability rank,

Tone
Negative 29/100
Event
Market update
Published
29 Jun 2026 22:39
Source
GuruFocus
Moomoo Direct company coverage

Biohaven Shares Down as Phase 3 Trial Concerns Trigger Downgrade at BofA

Biohaven Pharmaceutical shares have dropped due to concerns over its Phase 3 trial results for taldefgrobep alfa in spinal muscular atrophy (SMA). BofA Securities downgraded Biohaven from Buy to Neutral and lowered its price target to $30, citing the trial's failure to meet its p

Tone
Negative 26/100
Event
Analyst action
Published
29 Jun 2026 21:10
Source
Moomoo